Any weight loss from Ozempic or Mounjaro outside diabetes treatment is off-label
Chemico-Biological Interact
What We Will Cover: - Clinical Efficacy (ATTAIN Trials): A detailed review of the trials, including phase 3 data showcasing an average weight loss of 27.3 lbs (12.4%) at the highest dose over 72 weeks
After initiation of RYBELSUS or OZEMPIC tablets, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting
Compounding is now limited to narrow, patient-specific medical needs, not cost or convenience
For perspective on what these results look like in practice, real-world tirzepatide transformations confirm what the trials showed